Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction.Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million extension,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
